Original Article

Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone

Authors: Matthew W. Wilson, MD, Alex K. Bonnecaze, MD, Ajay Dharod, MD, Peter J. Miller, MD

Abstract

Objectives: Prescription drug abuse is a major public health problem in the United States, with the rate of opioid-related deaths nearly quadrupling between 2000 and 2014. Extended-release oral oxymorphone hydrochloride (Opana ER) is a long-acting opioid prescribed for chronic pain; however, it also has the potential to be abused via intravenous injection. This retrospective review sought to analyze specific complications and sequelae requiring intensive care unit resources for patients intravenously abusing extended-release oral oxymorphone.

Methods: We retrospectively reviewed the medical records of patients identified for drug abuse between January 2012 and December 2015, identifying patients who intravenously abused extended-release oral oxymorphone. Medical charts were reviewed to identify associated sequelae and patients requiring an intensive care unit level of care.

Results: We identified 53 patients who required treatment in an intensive care unit setting as a consequence of intravenously abusing extended-release oral oxymorphone. Twenty-eight patients (52.8%) required endotracheal intubation with mechanical ventilation for either acute hypoxic respiratory failure or protection of airway. Acute kidney injury developed in 48 patients (90.6%); 28.3% of these patients failed to regain renal function and required renal replacement therapy. Bacteremia was diagnosed in 36 patients (67.9%) and 30 patients (56.6%) were diagnosed as having acute infective bacterial endocarditis.

Conclusions: Our patients demonstrated a great need for critical care resources and severe sequelae related to intravenous drug abuse. Clinicians should be vigilant for the possibility for clinical decompensation when initially evaluating patients reporting intravenous abuse of extended-release oral oxymorphone.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. The United States war on drugs. https://web.stanford.edu/class/e297c/poverty_prejudice/paradox/htele.html. Accessed January 12, 2017.
 
2. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016;374:154-163.
 
3. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014;9:e97596.
 
4. Centers for Disease Control and Prevention. Prescription painkiller overdoses in the US, 2011. http://www.cdc.gov/vitalsigns/painkilleroverdoses. Published November 1, 2011. Accessed May 19, 2016.
 
5. North Carolina Injury and Violence Prevention. Prescription and drug overdoses. http://injuryfreenc.ncdhhs.gov/About/PoisoningOverdoseFactSheet2013.pdf. Published 2011. Accessed December 19, 2016.
 
6. Craig DS. Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain: a practical review for pharmacists. P T 2010;35:324-357.
 
7. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med 2016;375:229-239.
 
8. Centers for Disease Control and Prevention. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse-Tennessee, 2012. MMWR Morb Mortal Wkly Rep 2013;62:1-4.
 
9. Miller PJ, Farland AM, Knovich MA, et al. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Am J Hematol 2014;89:695-697.
 
10. Knovich MA, Farland A, Owen J. Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements. Eur J Haematol 2012;88:518-525.
 
11. Acute Kidney Injury Work Group. Kidney disease: improving global outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf. Published March 2012. Accessed January 12, 2017.
 
12. Hunt R, Yalamanoglu A, Baek JH, et al. A mechanistic investigation of the TTP-like state associated with intravenous abuse of Opana ER. Blood 2015;126:3521.
 
13. Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart 2002;88:53-60.